zffoto-shutterstock-com-1

Zffoto / Shutterstock.com

17 September 2015AmericasMercedes Meyer

Why CRISPR may define pre- and post-AIA changes

Polymerase chain reaction (PCR) revolutionised the ability of researchers to modify DNA strands and study gene action, gene mutations, and sequence the genomes of many organisms to learn more about ourselves at a molecular level. The ‘Queen et al patents’ helped pioneer human monoclonal antibody technology.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

CRISPR: careless talk costs patents

29 October 2015 Oppositions to a patent covering the CRISPR/Cas9 system illustrate the need for applicants to carefully consider making statements on commercially important technology even after a patent application has been filed. Catherine Coombes of law firm HGF reports.

Genetics

The CRISPR patent war

9 April 2015 The new CRISPR-Cas9 gene-editing system is set to revolutionise the treatment of genetic diseases, but there’s a fight to secure rights to the platform. LSIPR takes a look at the major players in this exciting technology area, and what patent disputes may arise as it develops.

More on this story

CRISPR: careless talk costs patents

29 October 2015 Oppositions to a patent covering the CRISPR/Cas9 system illustrate the need for applicants to carefully consider making statements on commercially important technology even after a patent application has been filed. Catherine Coombes of law firm HGF reports.

Genetics

The CRISPR patent war

9 April 2015 The new CRISPR-Cas9 gene-editing system is set to revolutionise the treatment of genetic diseases, but there’s a fight to secure rights to the platform. LSIPR takes a look at the major players in this exciting technology area, and what patent disputes may arise as it develops.

More on this story

CRISPR: careless talk costs patents

29 October 2015 Oppositions to a patent covering the CRISPR/Cas9 system illustrate the need for applicants to carefully consider making statements on commercially important technology even after a patent application has been filed. Catherine Coombes of law firm HGF reports.

Genetics

The CRISPR patent war

9 April 2015 The new CRISPR-Cas9 gene-editing system is set to revolutionise the treatment of genetic diseases, but there’s a fight to secure rights to the platform. LSIPR takes a look at the major players in this exciting technology area, and what patent disputes may arise as it develops.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed

Life sciences leaders recognised at LSPN Awards USA 2025

LSPN: Counsel grapple with AI’s impact on training and critical thinking

LSPN: Trump's policy storm causing chaos and confusion

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

ResMed voids sleep apnoea tech patent at PTAB

Novartis settles with licensee of blood cancer therapy day before trial

Foley adds five-partner team from Perkins Coie and K&L Gates